JP2003521470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521470A5 JP2003521470A5 JP2000609367A JP2000609367A JP2003521470A5 JP 2003521470 A5 JP2003521470 A5 JP 2003521470A5 JP 2000609367 A JP2000609367 A JP 2000609367A JP 2000609367 A JP2000609367 A JP 2000609367A JP 2003521470 A5 JP2003521470 A5 JP 2003521470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- venlafaxine
- human
- use according
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical class C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 31
- 150000003839 salts Chemical class 0.000 description 22
- 239000012453 solvate Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 229960004688 venlafaxine Drugs 0.000 description 7
- 206010021639 Incontinence Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000017194 Affective disease Diseases 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008138 Cerebral venous thrombosis Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12793899P | 1999-04-06 | 1999-04-06 | |
| US60/127,938 | 1999-04-06 | ||
| US16790699P | 1999-11-30 | 1999-11-30 | |
| US60/167,906 | 1999-11-30 | ||
| PCT/US2000/008705 WO2000059851A1 (en) | 1999-04-06 | 2000-03-31 | Derivatives of venlafaxine and methods of preparing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003521470A JP2003521470A (ja) | 2003-07-15 |
| JP2003521470A5 true JP2003521470A5 (https=) | 2007-04-19 |
Family
ID=26826101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609367A Pending JP2003521470A (ja) | 1999-04-06 | 2000-03-31 | ベンラファキシンの誘導体とその調製および使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8269040B2 (https=) |
| EP (4) | EP1905757A1 (https=) |
| JP (1) | JP2003521470A (https=) |
| AT (1) | ATE397581T1 (https=) |
| AU (2) | AU782092B2 (https=) |
| CA (1) | CA2368083A1 (https=) |
| CY (1) | CY1108202T1 (https=) |
| CZ (1) | CZ20013607A3 (https=) |
| DE (1) | DE60039132D1 (https=) |
| DK (1) | DK1466889T3 (https=) |
| ES (1) | ES2305606T3 (https=) |
| HU (1) | HUP0200898A3 (https=) |
| NO (2) | NO20014816L (https=) |
| NZ (1) | NZ514612A (https=) |
| PL (1) | PL350924A1 (https=) |
| PT (1) | PT1466889E (https=) |
| WO (1) | WO2000059851A1 (https=) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| DE60039132D1 (de) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-Desmethylvenlafaxin-Succinat |
| DE10042412B4 (de) * | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
| EP1864967A1 (en) | 2001-02-12 | 2007-12-12 | Wyeth | Method for preparing O-desmethyl-venlafaxine |
| UA80543C2 (en) | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
| EP1485344A1 (en) * | 2002-03-28 | 2004-12-15 | Synthon B.V. | Venlafaxine besylate |
| US6696496B2 (en) * | 2002-03-28 | 2004-02-24 | Synthon Bv | Low water-soluble venlafaxine salts |
| EP3173082A1 (en) * | 2002-05-17 | 2017-05-31 | Duke University | Method for treating obesity |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| NZ537142A (en) | 2002-06-10 | 2008-01-31 | Wyeth Corp | Novel formate salt of O-desmethyl-venlafaxine |
| TWI306092B (en) | 2003-03-11 | 2009-02-11 | Wyeth Corp | Process for preparation of phenethylamine derivatives |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
| US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
| US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| CA2554559A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
| CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
| JP2008509142A (ja) * | 2004-08-03 | 2008-03-27 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ |
| KR100693528B1 (ko) * | 2004-10-29 | 2007-03-14 | 주식회사 팬택 | 전원 지연 인가 기능을 가지는 무선통신 단말기 |
| EP1721889A1 (en) * | 2005-05-12 | 2006-11-15 | Dishman Pharmaceuticals & Chemicals Ltd. | Process for the preparation of phenethylamine derivatives |
| CA2614209A1 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| GT200600396A (es) * | 2005-09-07 | 2007-04-23 | Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales | |
| GT200600397A (es) * | 2005-09-07 | 2007-08-28 | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales | |
| CA2625832A1 (en) * | 2005-10-19 | 2007-04-26 | Vinod Kumar Kansal | Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| EP1973866A1 (en) * | 2005-12-20 | 2008-10-01 | Synthon B.V. | Process for making desvenlafaxine |
| MX2007016179A (es) * | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| WO2007120923A1 (en) | 2006-04-17 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Substantially pure o-desmethylvenlafaxine and processes for preparing it |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| EP1870395A1 (en) * | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
| EP2081885A2 (en) * | 2006-07-14 | 2009-07-29 | Medichem, S.A. | Improved processes for preparing venlafaxine base and salts thereof |
| US20090062572A1 (en) * | 2006-07-26 | 2009-03-05 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
| US20090069601A1 (en) * | 2006-07-26 | 2009-03-12 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
| US20090137846A1 (en) * | 2006-07-26 | 2009-05-28 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-Desmethylvenlafaxine |
| WO2008013993A2 (en) * | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of o-desmethylvenlafaxine |
| WO2008013994A2 (en) | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of o-desmethylvenlafaxine |
| US20080221356A1 (en) * | 2006-07-26 | 2008-09-11 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
| WO2008013995A2 (en) * | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine |
| EP2061750A2 (en) * | 2006-08-04 | 2009-05-27 | Medichem, S.A. | Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof |
| CA2659295A1 (en) * | 2006-08-08 | 2008-02-14 | Generics [Uk] Limited | Novel hydrate form of o-desmethyl venlafaxine succinate |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| DK2089005T3 (da) | 2006-11-09 | 2010-07-19 | Orexigen Therapeutics Inc | Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| AR064987A1 (es) * | 2007-01-22 | 2009-05-06 | Medichem Sa | Proceso mejorado para sintetizar desvenlafaxina como base libre y sales o solvatos de la misma |
| IN2009DN05509A (https=) * | 2007-03-14 | 2010-04-30 | Teva Pharma | |
| EP2455076A1 (en) * | 2007-04-09 | 2012-05-23 | Sepracor Inc. | Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders |
| WO2009010990A2 (en) * | 2007-07-16 | 2009-01-22 | Matrix Laboratories Limited | Process for the preparation of o-desmethylvenlafaxine succinate polymorphic forms |
| AU2008315740A1 (en) | 2007-10-26 | 2009-04-30 | Generics [Uk] Limited | Process for preparing O-desmethylvenlafaxine |
| WO2009070311A2 (en) | 2007-11-26 | 2009-06-04 | Teva Pharmaceutical Industries Ltd. | Crystal forms of o-desmethylvenlafaxine fumarate |
| WO2009151494A1 (en) * | 2008-03-06 | 2009-12-17 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities |
| EP2119695A1 (en) | 2008-05-16 | 2009-11-18 | Krka | Preparation of O-desmethylvenlafaxine salts |
| EP2119696A1 (en) | 2008-05-16 | 2009-11-18 | Krka | Preparation of O-desmethylvenlafaxine salts |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2720538A1 (en) * | 2008-06-16 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Solid states of o-desmethylvenlafaxine salts |
| ES2343050B1 (es) * | 2008-12-16 | 2011-06-14 | Chemo Iberica, S.A. | Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables. |
| EP2398468B1 (en) | 2009-02-17 | 2016-11-30 | KRKA, D.D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
| CN101823969A (zh) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | 一种去甲文拉法辛的制备方法 |
| WO2011007136A2 (en) | 2009-07-16 | 2011-01-20 | Cipla Limited | Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein |
| AU2009356897A1 (en) | 2009-12-16 | 2012-08-09 | Pharmathen S.A. | Process for the preparation of O-desmethyl-venlafaxine and salts thereof |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| WO2011121452A2 (en) | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
| CZ303249B6 (cs) | 2010-04-06 | 2012-06-20 | Zentiva, K.S. | Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu |
| SG188637A1 (en) * | 2010-10-01 | 2013-05-31 | Shan Dong Luye Pharm Co Ltd | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same |
| BR112013025766A2 (pt) | 2011-04-12 | 2016-12-20 | Lupin Ltd | composições farmacêuticas de liberação modificada de desvenlafaxina |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167990A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| CN104364231A (zh) | 2012-09-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | 用于治疗炎症和脂质异常的组合物和方法 |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| JP6698643B2 (ja) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための組成物及び方法 |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CA2973178C (en) | 2015-01-06 | 2022-11-01 | Cellix Bio Private Limited | Bupivacaine derivatives and their use in the treatment of inflammation and pain |
| CN104628582B (zh) * | 2015-01-29 | 2016-08-24 | 济南爱思医药科技有限公司 | 一种去甲文拉法辛盐酸盐的制备方法 |
| MX367362B (es) | 2016-06-29 | 2019-08-16 | Alparis Sa De Cv | Nuevas formas solidas de desvenlafaxina. |
| AR109760A1 (es) | 2016-09-30 | 2019-01-23 | Biotie Therapies Inc | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson |
| EP3580198B1 (en) | 2017-02-09 | 2023-08-09 | R L Finechem Private Limited | A process for preparation of1-[2-(dimethylamino)-1-(4-hydroxyphenyl) ethyl]-cyclohexanol and salts thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE2726676C2 (de) * | 1977-06-14 | 1983-06-30 | Lemförder Metallwaren AG, 2844 Lemförde | Federelement zur elastischen Lagerung von Antriebs- oder sonstigen Aggregaten |
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
| ZA839073B (en) * | 1982-12-13 | 1984-09-26 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| ATE64735T1 (de) * | 1984-05-10 | 1991-07-15 | Ciba Geigy Ag | Benzo-(pyrano und thiopyrano)-pyridine. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| DE3514268A1 (de) * | 1985-04-19 | 1986-10-23 | Metzeler Kautschuk GmbH, 8000 München | Vorspannbares und hydraulisches gedaempftes lagerelement |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| GB8902209D0 (en) * | 1989-02-01 | 1989-03-22 | Wyeth John And Brother Limited | Preparation of cyclohexanol derivatives and novel thioamide intermediates |
| DE3905686C1 (https=) * | 1989-02-24 | 1990-06-07 | Fa. Carl Freudenberg, 6940 Weinheim, De | |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| AU4542993A (en) * | 1992-06-23 | 1994-01-24 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
| AU4542893A (en) | 1992-06-23 | 1994-01-24 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| PT639374E (pt) * | 1993-06-28 | 2002-07-31 | American Home Prod | Novos tratamentos utilizado derivados fenetilo |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| CA2176722A1 (en) * | 1993-12-28 | 1995-07-06 | Ruth E. Ten Brink | Heterocyclic compounds for the treatment of cns and cardiovascular disorders |
| ATE229328T1 (de) * | 1994-02-14 | 2002-12-15 | Wyeth Corp | Venlafaxin und seine analoga zum herbeiführen einer verbesserung der kognitiven funktionen |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5506270A (en) * | 1995-01-30 | 1996-04-09 | American Home Products Corporation | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5541199A (en) * | 1995-06-02 | 1996-07-30 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| JPH08333340A (ja) * | 1995-06-06 | 1996-12-17 | Fujirebio Inc | アミノエチルピペリジン誘導体の製造方法 |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| DE19613912C2 (de) * | 1996-04-06 | 2001-02-15 | Boge Gmbh | Hydraulisch dämpfendes Gummilager |
| AU3075197A (en) | 1996-05-21 | 1997-12-09 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Novel methods of o-demethylation and n-deprotection |
| AU4894697A (en) | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
| UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
| US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| DE60039132D1 (de) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-Desmethylvenlafaxin-Succinat |
| CA2371836C (en) | 1999-05-27 | 2006-01-31 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US20020022662A1 (en) * | 1999-06-15 | 2002-02-21 | American Home Products Corporation | Enantiomers of O-desmethyl venlafaxine |
| WO2000076955A1 (en) | 1999-06-15 | 2000-12-21 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
| EP1864967A1 (en) * | 2001-02-12 | 2007-12-12 | Wyeth | Method for preparing O-desmethyl-venlafaxine |
| UA80543C2 (en) * | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
| NZ537142A (en) * | 2002-06-10 | 2008-01-31 | Wyeth Corp | Novel formate salt of O-desmethyl-venlafaxine |
| TWI306092B (en) * | 2003-03-11 | 2009-02-11 | Wyeth Corp | Process for preparation of phenethylamine derivatives |
| CA2554559A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
-
2000
- 2000-03-31 DE DE60039132T patent/DE60039132D1/de not_active Revoked
- 2000-03-31 EP EP07120213A patent/EP1905757A1/en not_active Withdrawn
- 2000-03-31 EP EP00920026A patent/EP1165487A1/en not_active Ceased
- 2000-03-31 JP JP2000609367A patent/JP2003521470A/ja active Pending
- 2000-03-31 HU HU0200898A patent/HUP0200898A3/hu unknown
- 2000-03-31 PT PT04010248T patent/PT1466889E/pt unknown
- 2000-03-31 CA CA002368083A patent/CA2368083A1/en not_active Abandoned
- 2000-03-31 WO PCT/US2000/008705 patent/WO2000059851A1/en not_active Ceased
- 2000-03-31 AU AU40627/00A patent/AU782092B2/en not_active Expired
- 2000-03-31 PL PL00350924A patent/PL350924A1/xx not_active Application Discontinuation
- 2000-03-31 CZ CZ20013607A patent/CZ20013607A3/cs unknown
- 2000-03-31 EP EP09171838A patent/EP2133325A1/en not_active Withdrawn
- 2000-03-31 AT AT04010248T patent/ATE397581T1/de not_active IP Right Cessation
- 2000-03-31 EP EP04010248A patent/EP1466889B1/en not_active Revoked
- 2000-03-31 ES ES04010248T patent/ES2305606T3/es not_active Expired - Lifetime
- 2000-03-31 NZ NZ514612A patent/NZ514612A/xx not_active IP Right Cessation
- 2000-03-31 DK DK04010248T patent/DK1466889T3/da active
-
2001
- 2001-10-03 NO NO20014816A patent/NO20014816L/no not_active Application Discontinuation
-
2003
- 2003-11-25 US US10/720,134 patent/US8269040B2/en active Active
-
2005
- 2005-03-29 US US11/091,518 patent/US20050197392A1/en not_active Abandoned
- 2005-09-30 AU AU2005218047A patent/AU2005218047B2/en not_active Expired
-
2008
- 2008-01-23 US US12/011,083 patent/US20080132578A1/en not_active Abandoned
- 2008-07-18 CY CY20081100751T patent/CY1108202T1/el unknown
-
2010
- 2010-04-07 NO NO20100496A patent/NO20100496L/no not_active Application Discontinuation
-
2012
- 2012-08-09 US US13/570,412 patent/US20120302794A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003521470A5 (https=) | ||
| JP2003524613A5 (https=) | ||
| JP2003501344A5 (https=) | ||
| CA2352324A1 (en) | Derivatives of (-)-venlafaxine and methods of preparing and using the same | |
| Subedi et al. | An overview of tramadol and its usage in pain management and future perspective | |
| JP2002523366A5 (https=) | ||
| JP2017222679A (ja) | 医薬組成物 | |
| CA2341441A1 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| CN1980667A (zh) | 治疗、预防或控制不良睡眠和不良睡眠相关疾病的方法和组合物 | |
| JP2006527256A5 (https=) | ||
| RU2009135016A (ru) | Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения | |
| TWI838826B (zh) | Ｌｓｄ的固體口服立即釋放配製物的組成物及製作ｌｓｄ的固體口服立即釋放配製物之方法 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| AU2005205882A1 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | |
| JP2018203774A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| CN104013638A (zh) | 当药黄素及其衍生物的用途 | |
| JPS61286326A (ja) | パ−キンソン病治療薬 | |
| JP2016539994A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| JP2008531594A5 (https=) | ||
| JP7653429B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| MXPA05000791A (es) | Compuestos de 1-fenil-2-dimetilaminometil ciclohexano para la terapia de sintomas depresivos, dolor e incontinencia. | |
| US20130296414A1 (en) | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence | |
| US20100130554A1 (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease | |
| AU2005231479C1 (en) | (R,R)-formoterol in combination with other pharmacological agents | |
| US20050228052A1 (en) | Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine |